Class I phosphoinositide 3-kinases in immunity: Effect of inhibitors in immune and autoimmune reactions

Rojo, José María; Portolés, Pilar.
An. R. Acad. Farm ; 80(1): 91-125, ene.-mar. 2014. ilus, tab
Artículo en Inglés | IBECS (España) | ID: ibc-121838

Documentos relacionados

  1. TYK2 inhibition and its potential in the treatment of chronic inflammatory immune diseases.
  2. Systems Chronotherapeutics.
  3. Modulation of antigen processing by haem-oxygenase 1. Implications on inflammation and tolerance.
  4. LAG-3 as the third checkpoint inhibitor.
  5. Associations between plasma hydroxylated metabolite of itraconazole and serum creatinine in patients with a hematopoietic or immune-related disorder.
  6. [Pathogenesis and treatment of immune dysregulation associated with myelodysplastic syndromes].
  7. CRISPR/Cas9 guided genome and epigenome engineering and its therapeutic applications in immune mediated diseases.
  8. IgG4 anti-infliximab in treated patients: Clinical impact and temporal evolution.
  9. Cytokine release: A workshop proceedings on the state-of-the-science, current challenges and future directions.
  10. Acute immune toxicity during anti-thymocyte globulin: That's CARPA!